Cash & equivalents increased 59.0%
Cash & equivalents changed +59.0% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Cash & equivalents changed +59.0% from the comparable as-filed period.
Research & development changed +61.7% from the comparable as-filed period.
Gross profit changed +8.4% from the comparable as-filed period.
Inventory changed +7.7% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Net income changed +8.1% from the comparable as-filed period.
Operating income changed +6.6% from the comparable as-filed period.
Revenue changed +8.9% from the comparable as-filed period.
Selling, general & administrative changed +6.3% from the comparable as-filed period.
Gross margin changed -13 basis points from the comparable as-filed period.
Operating margin changed -45 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.